Annual highlights
* Sales USD 335.6 million, up by 33% from 2006
* Organic sales growth 7%
* EBITDA USD 64.4 million, up by 63% from 2006
* EBITDA adjusted USD 58.4 million, up by 22% from 2006
* Net profit USD 7.6 million, up by 74% from 2006
* Cash EPS diluted 8.24 US cents, up by 31% from 2006
* EPS diluted 1.94 US cents, up by 71% from 2006
* Equity offering completed in November.
Q4 highlights
* Sales 84.9 million, up 33% from Q4 2006
* Organic sales growth 4%
* EBITDA USD 22.7 million, up by 305% from Q4 2006
* EBITDA adjusted USD 13.5 million, up by 22% from Q4 2006
Jon Sigurdsson, President & CEO, comments:"The year was characterized by strong organic growth in prosthetics,
restructuring in the Americas and internal focus. The growth we are
seeing in the prosthetics confirms our technical leadership in this
segment and that we are harvesting from our efforts in the past to
restructure and create one sales force following acquisitions made in
the prosthetic segment in the year 2000. We have completed numerous
acquisitions since 2005 making our entrance into the bracing and
support segment of the non-invasive orthopaedics market. To fully
leverage the synergies from these acquisitions our focus has been on
completing the restructuring of the bracing and support sales channel
in the Americas which has been affecting our bracing and support
sales performance in 2007. The Bionic Technology platform and other
innovations are the result of significant and ongoing investments in
research and development. We have also introduced numerous new
products and product upgrades in the bracing and support segment
which have been well received by professionals confirming the need
for new products in this segment. We are confident that a turnaround
in the bracing and support sales is on the horizon and that in 2008
we will see results of our efforts."
Live comments form the CEO, see link here below:
www.ossur.com/ceocomments
